This phase III trial will compare the safety and effectiveness of two targeted cancer drugs in patients with HER-2 positive, invasive breast cancer following neoadjuvant therapy.
This trial is treating patients with breast cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had a certain type of treatment or surgical procedure.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Participants With High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy (DESTINY-Breast05)
Daiichi Sankyo, Inc.
Eligible patients will be randomised to receive trastuzumab deruxtecan (T-DXd) at a starting dose of 5.4 mg/kg or trastuzumab ematansine (T-DM1) at a starting dose of 3.6 mg/kg.
Recruiting Hospitals Read More